What You Should Know:
- ALZpath, a developer of blood-based diagnostic biomarker testing for Alzheimer's disease detection receives funding from the Alzheimer’s Drug Discovery Foundation (ADDF)’s Diagnostics Accelerator to accelerate the clinical availability of ALZpathDx as a laboratory developed test (LDT).
- ALZpathDx is a novel, proprietary assay for blood-based measurement of phosphorylated tau at threonine 217 (pTau217), a highly accurate, diagnostic biomarker for
Read More
Alzheimer’s disease
Are Hospitals Ready for Alzheimer’s Treatment Approval?
The FDA’s recent accelerated approval of Leqembi was welcome news across the Alzheimer’s community. However, few health systems, medical practices, or providers are prepared for the extraordinary public interest in a treatment for Alzheimer’s disease – especially not one targeting mild cognitive impairment (MCI) and early dementia due to Alzheimer’s disease – that is likely headed their way soon. The unprecedented scale of the public health and marketing campaigns, the high prevalence of MCI in
Read More
Real-World Study Uses AI to Identify Undiagnosed Dementia in Primary Care
What You Should Know:
- Rising to meet the formidable challenge of the timely diagnosis of dementia, research scientists from Regenstrief Institute, IUPUI and the medical schools of Indiana University and the University of Miami are conducting the Digital Detection of Dementia study, a real-world evaluation of the use of an artificial intelligence (AI) tool they developed for early identification of Alzheimer’s disease and related dementias in primary care, the setting where most adults
Read More
Clinical Trials: 5 Steps to Greater eConsent Adoption
Clinical trials advance much-needed treatments while offering hope to patients and their families. However, the process of enrolling in a study where they will receive investigational medicines, vaccines or procedures can be a source of friction – enough for patients to rethink participation.
The weight of the decision combined with a perceived lack of transparency of information can confuse or dismay even those patients that are most savvy in the medical industry. Even if they do end
Read More
The Gains and Pains of Using AI in the Pharmaceutical Industry
The costs for drug discovery and development are skyrocketing, but AI (artificial intelligence) is introducing new efficiencies to help find effective treatments faster.
A study in 2020 concluded that the estimated median capitalized research and development cost per product was $985 million. Contributing factors to this included larger trial sizes, the need to assess health technology, the requirement to provide data on comparative drugs’ effectiveness, and most
Read More
Eyenuk Raises $26M for AI-Powered Eye Screening & Predictive Biomarkers
What You Should Know:
- Eyenuk, Inc., a global artificial intelligence (AI) digital health company and the leader in real-world applications for AI Eye Screening™ and AI Predictive Biomarkers™, today announced it has secured $26 million in a Series A financing round, bringing the Company’s total funding to over $43 million.
- The capital raise was led by AXA IM Alts and was joined by new and existing investors including T&W Medical A/S, A&C Foelsgaard Alternativer ApS, Kendall
Read More
Brain Health: The Next Frontier in the Fight Against Dementia
There are differing views on the value of cognitive screening of older adults in a primary care setting. Many providers point to the lack of disease-modifying treatments for Alzheimer’s Dementia and related dementias (ADRD) as a reason to not universally screen older adults for cognitive deficits. If I don’t have anything to give my patients to get better, what’s the point in revealing they might be at risk of dementia, or that they have early disease? Is dementia a ‘normal’ or ‘expected’ part
Read More
Rippl Launches with $35M to Transform Mental Health for Seniors
What You Should Know:
- Rippl, a new mental health startup focused on caring for seniors with dementia and other neurocognitive conditions, launched today with $32M in seed round funding led by ARCH Venture Partners and General Catalyst. The round also includes investment from GV, F-Prime Capital, and Mass General Brigham Ventures.
- Rippl will use its seed funding to hire and train a team of clinicians, build technology, and open a Washington state-based clinical support center to launch
Read More
Linus Health Launches AI Platform to Detect, Delay Dementia
What You Should Know:
- Linus Health launches the first iPad-based cognitive screening platform able to detect cognitive decline such as dementia years before the human eye could ever do so.
- Linus is now offering a solution to empower PCPs to not only pinpoint cognitive issues in just minutes but also leverage AI to provide patients with evidence-based early interventions
IPad-Based Brain Health Platform
Projections estimate that the number of people in the US with Alzheimer's
Read More
NeuroSense Therapeutics and NeuraLight Collaborate to Detect ALS Oculometric Biomarkers
What You Should Know:
- NeuroSense Therapeutics Ltd., a company developing treatments for severe neurodegenerative diseases, and NeuraLight, a company developing objective and sensitive biomarkers for neurological disorders, today announced a collaboration to advance the science of digital biomarkers in the detection and monitoring of neurological diseases including amyotrophic lateral sclerosis (ALS).
- This agreement marks NeuraLight’s first clinical trial and comes on the heels of
Read More
